



Ekaterina S. Jordanova, PhD

Principle Investigator

Centre for Gynaecologic Oncology Amsterdam, VUmc/AMC/NKI_AVL, The Netherlands

EDUCATION

1. Master Degree, Molecular and Cellular Biology, 1997, Vrije Universiteit, Amsterdam, The Netherlands.
2. PhD Thesis: Somatic Alterations of Chromosome 6p21 and HLA Protein Expression in B-cell Lymphoma. 1999-2004; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

EMPLOYMENT

1. Postdoctoral position at the Department of Pathology. 2003-2017. Leiden University Medical Center, Leiden, The Netherlands.
3. Scientific advisor and supervisor, the Female Cancer Foundation in Indonesia. 2008-2010.
4. Involved as a senior scientist in the lymphoma diagnostics at the Pathology Department, VUmc, Amsterdam, The Netherlands. 2012-current.
5. Senior Scientist/PI at the Center for Gynecologic Oncology Amsterdam (VUmc/AMC/NKI_AVL). Amsterdam, The Netherlands. 2011-current.

RELEVANT PROFESSIONAL ACTIVITIES

- Supervisor of 12 PhD students from 2007. Currently supervising 8 PhD candidates.
- Member of the Dutch Immunology Association
- 2014 – present Member EORTC GCG group
- Ambassador Inter-cultural Committee of the VUmc, Amsterdam

Dr. Ekaterina Jordanova is a molecular biologist/principle investigator at the Centre for Gynaecologic Oncology Amsterdam. Her major field of expertise is epidemiology, genetics, and immunology of HPV induced cancers, such as head and neck-, vulvar-, penile- and cervical cancer. She has established a research program on the role of the immune microenvironment in HPV-induced cancer development and progression using state-of-the art techniques such as multispectral immunohistochemistry. In addition, she is involved in several immunotherapy clinical trials of HPV-induced cancers. Dr. Jordanova is author on more than one hundred publications on cancer.

Publications 2012-2017

1. Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study. Samuels S, Balint B, von der Leyen H, Hupé P, de Koning L, Kamoun C, Luscap-Rondof W, Wittkop U, Bagrintseva K, Popovic M, Kereszt A, Berns E, Kenter GG, **Jordanova ES**, Kamal M, Scholl S. *Br J Cancer*. 2016 Dec 6;115(12):1575-1583.
2. Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status. Ottenhof SR, Djajadiningrat RS, de Jong J, Thygesen HH, Horenblas S, **Jordanova ES**. *J Urol*. 2016 Sep 30. pii: S0022-5347(16)31407-0.
3. Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Heeren AM, de Boer E, Bleeker MC, Musters RJ, Buist MR, Kenter GG, de Gruijl TD, **Jordanova ES**. *Oncotarget*. 2015 Oct 20;6(32):32484-93.
4. Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome. Spaans VM, Trietsch MD, Peters AA, Osse M, Ter Haar N, Fleuren GJ, **Jordanova ES**. *PLoS One*. 2015 Jul 21;10(7):e0133670.
5. Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy. van Esch EM, Tummers B, Baartmans V, Osse EM, Ter Haar N, Trietsch MD, Hellebrekers BW, Holleboom CA, Nagel HT, Tan LT, Fleuren GJ, van Poelgeest MI, van der Burg SH, **Jordanova ES**. *Int J Cancer*. 2014 Aug 15;135(4):830-42.